Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects

NCT02446847 is registered in ClinicalTrials.gov with Rockefeller University as lead sponsor.

NCT NCT02446847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects
Lead sponsor
Rockefeller University
Phase
Phase 2
Overall status
Completed
Start date
March 11, 2015
Completion date
March 25, 2017
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection